Compare SVC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | QURE |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2013 |
| Metric | SVC | QURE |
|---|---|---|
| Price | $1.65 | $46.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $2.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 5.9M | 2.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | 26.95 | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,814,838,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | $1.39 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $8.73 |
| 52 Week High | $3.08 | $71.50 |
| Indicator | SVC | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 79.16 |
| Support Level | $1.66 | $21.63 |
| Resistance Level | $1.83 | $60.70 |
| Average True Range (ATR) | 0.07 | 2.43 |
| MACD | -0.01 | 1.72 |
| Stochastic Oscillator | 63.15 | 84.49 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.